

Christos Chouaid

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4449967/christos-chouaid-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

236
papers

10,094
citations

43
h-index

95
g-index

346
ext. papers

12,292
ext. citations

4.4
avg, IF

5.56
L-index

#	Paper	IF	Citations
236	Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.. <i>Current Oncology</i> , 2022 , 29, 641-658	2.8	0
235	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data.. <i>BioDrugs</i> , 2022 , 36, 137	7.9	0
234	Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100108 ¹	5.2	108 ¹
233	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.. <i>Targeted Oncology</i> , 2022 , 17, 153	5	0
232	Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.. <i>Lung Cancer</i> , 2022 , 166, 205-220	5.9	0
231	Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods.. <i>Medical and Biological Engineering and Computing</i> , 2022 , 60, 1647	3.1	0
230	Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in FranceDeclarations of financial/other interest.. <i>Journal of Medical Economics</i> , 2022 , 1-22	2.4	
229	A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. <i>Targeted Oncology</i> , 2021 , 16, 801-811	5	1
228	Factors associated with early lung cancer mortality: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1125-1133	3.5	1
227	Economic analyses of immune-checkpoint inhibitors to treat lung cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 21, 365-371	2.2	
226	Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211006983	5.4	2
225	Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. <i>Cancers</i> , 2021 , 13,	6.6	1
224	Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. <i>Cancers</i> , 2021 , 13,	6.6	3
223	Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	5
222	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥ 0 . <i>Future Oncology</i> , 2021 , 17, 3007-3016	3.6	4
221	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. <i>Lung Cancer</i> , 2021 , 159, 45-55	5.9	4
220	Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14). <i>Current Oncology</i> , 2021 , 28, 3804-3811	2.8	0

219	Efficacy of Dabrafenib Plus Trametinib Combination in Patients with V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. <i>Cancers</i> , 2020 , 12,	6.6	2
218	Duration of nivolumab for pretreated, advanced non-small-cell lung cancer. <i>Cancer Medicine</i> , 2020 , 9, 6923-6932	4.8	4
217	Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. <i>OncoTargets and Therapy</i> , 2020 , 13, 5691-5706	4.4	8
216	Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
215	PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920937972	5.4	9
214	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 628-636	8.9	82
213	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020 , 99, e18726	1.8	16
212	First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥1% in a multicenter real-life cohort: The PEMBREIZH study. <i>Cancer Medicine</i> , 2020 , 9, 2309-2316	4.8	19
211	Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in -mutated non-small-cell lung cancer: a real life study. <i>Future Oncology</i> , 2020 , 16, 1115-1124	2.6	1
210	Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). <i>OncoTargets and Therapy</i> , 2020 , 13, 13299-13305	4.4	0
209	Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. <i>Lung Cancer</i> , 2020 , 140, 99-106	5.9	46
208	Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017). <i>Future Oncology</i> , 2020 , 16, 5-10	3.6	6
207	Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. <i>Lung Cancer</i> , 2020 , 150, 21-25	5.9	19
206	Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. <i>Lung Cancer</i> , 2020 , 147, 137-142	5.9	13
205	Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e546	21.7	1
204	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. <i>Cancers</i> , 2020 , 12,	6.6	20
203	Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1224-1233	21.7	24
202	Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920967237	5.4	5

201	First-line immune-checkpoint inhibitor plus chemotherapy chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920977137	5.4	137
200	Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 1929-1939	4.0	582
199	Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. <i>Current Medical Research and Opinion</i> , 2019 , 35, 785-792	2.5	10
198	Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14. <i>Advances in Therapy</i> , 2019 , 36, 2161-2166	4.1	6
197	Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2019 , 14, 307-314	5	2
196	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2019 , 33, 159-171	7.9	33
195	Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. <i>Translational Oncology</i> , 2019 , 12, 784-787	4.9	2
194	I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. <i>Future Oncology</i> , 2019 , 15, 1551-1563	3.6	11
193	Lung cancer survivors and employment: A systematic review. <i>Lung Cancer</i> , 2019 , 131, 31-39	5.9	6
192	Nivolumab-refractory patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019 , 130, 128-134	4.9	12
191	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019 , 136, 109-114	5.9	13
190	Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy. <i>International Journal of COPD</i> , 2019 , 14, 2905-2915	3	2
189	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. <i>Lung Cancer</i> , 2019 , 127, 96-102	5.9	23
188	Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB). <i>PLoS ONE</i> , 2019 , 14, e0208992	3.7	4
187	Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. <i>Lung Cancer</i> , 2019 , 127, 44-52	5.9	30
186	Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. <i>Cancer Medicine</i> , 2018 , 7, 1102-1109	4.8	11
185	Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018 , 4,	3.5	6
184	Beclin1 circulating levels and accelerated aging markers in COPD. <i>Cell Death and Disease</i> , 2018 , 9, 156	9.8	5

183	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018 , 116, 62-66	5.9	69
182	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 576-584	8.9	45
181	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2018 , 19, 521-536	21.7	315
180	Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). <i>Oncology</i> , 2018 , 94, 55-64	3.6	13
179	Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. <i>Targeted Oncology</i> , 2018 , 13, 501-507	5	24
178	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. <i>OncoTargets and Therapy</i> , 2018 , 11, 4051-4064	4.4	10
177	Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 981-989	3.5	9
176	Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. <i>ERJ Open Research</i> , 2018 , 4,	3.5	14
175	Adjuvant treatment patterns and outcomes in patients with stage IB-IIIa non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. <i>Lung Cancer</i> , 2018 , 124, 310-316	5.9	11
174	Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018 , 18, 519-528	2.2	12
173	Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach. <i>Scientific Reports</i> , 2018 , 8, 8569	4.9	3
172	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <i>Oncotarget</i> , 2018 , 9, 8253-8262	3.3	15
171	Lung cancer and interstitial lung disease: a literature review. <i>Journal of Thoracic Disease</i> , 2018 , 10, 3829-3844	3.4	57
170	Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France. <i>Oncology</i> , 2018 , 95, 337-343	3.6	9
169	Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. <i>BMC Cancer</i> , 2018 , 18, 1013	4.8	2
168	Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. <i>Cancer Medicine</i> , 2018 , 7, 5505-5513	4.8	27
167	Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 1159-1165	3.5	2
166	Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). <i>Lung Cancer</i> , 2018 , 121, 25-29	5.9	7

165	Economic burden of resected (stage IB-IIIa) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). <i>Lung Cancer</i> , 2018 , 124, 298-309	5.9	12
164	Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations. <i>BMC Public Health</i> , 2017 , 17, 191	4.1	13
163	Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. <i>BMC Public Health</i> , 2017 , 17, 324	4.1	4
162	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017 , 12, 563-569	5	50
161	Association between lung cancer somatic mutations and occupational exposure in never-smokers. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	7
160	PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. <i>International Journal of Technology Assessment in Health Care</i> , 2017 , 33, 609-619	1.8	5
159	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 655-668	1.7	8
158	A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 505-518	1.7	5
157	Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. <i>Journal of Thoracic Disease</i> , 2017 , 9, 3747-3754	2.6	8
156	Second-line treatments of small-cell lung cancers. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 1033-1043	4.3	13
155	Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 140, 1754-1757.e6	11.5	5
154	Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1496-1502	8.9	27
153	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). <i>Targeted Oncology</i> , 2017 , 12, 833-838	5	7
152	Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment. <i>Journal of Market Access & Health Policy</i> , 2017 , 5, 1344088	3.7	14
151	Author's Reply to Arnaud Uguen: "Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study)". <i>Targeted Oncology</i> , 2017 , 12, 841-842	5	1
150	Cost analysis of adverse events associated with non-small cell lung cancer management in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 443-449	1.7	4
149	Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study). <i>PLoS ONE</i> , 2017 , 12, e0182798	3.7	17
148	Cost-effectiveness analysis of afatinib vs gefitinib in EGFR-mutated population with advanced non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20548-e20548	2.2	

147	Management of patients with head and neck cancer (HNC) and synchronic stage I or II lung cancer. SYNCHRON GFPC 15-01 study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20048-e20048	2.2	
146	Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. <i>Respiratory Medicine</i> , 2016 , 117, 33-9	4.6	27
145	French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. <i>Targeted Oncology</i> , 2016 , 11, 515-34	5	8
144	Delays for diagnosis and treatment of lung cancers: a systematic review. <i>Clinical Respiratory Journal</i> , 2016 , 10, 267-71	1.7	34
143	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. <i>Targeted Oncology</i> , 2016 , 11, 167-74	5	15
142	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016 , 27, 417-23	19.3	101
141	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 801-7	8.9	16
140	Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1476-83	2.2	239
139	Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. <i>European Journal of Cancer</i> , 2016 , 52, 181-7	7.5	15
138	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , 2016 , 17, 212-223	21.7	110
137	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20522-e20522	2.2	5
136	Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. <i>PLoS ONE</i> , 2016 , 11, e0156514	3.7	7
135	Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20555-e20555 ⁰	2.2	
134	Targeted therapy for localized non-small-cell lung cancer: a review. <i>OncoTargets and Therapy</i> , 2016 , 9, 4099-104	4.4	21
133	Immunoth�apie : un nouveau paradigme dans la prise en charge du cancer bronchique non ^ petites cellules. <i>Oncologie</i> , 2016 , 18, 365-370	1	1
132	Le d�istage du cancer bronchopulmonaire par tomodensitom�trie thoracique ^ faible dose en France : enjeux et perspectives. <i>Oncologie</i> , 2016 , 18, 392-396	1	1
131	Prise en charge des m�tastases c�brales des cancers du poumon. <i>Oncologie</i> , 2016 , 18, 376-384	1	1
130	Burden of Disease And Management of Mesothelioma In France: A National Cohort Analysis. <i>Value in Health</i> , 2016 , 19, A621	3.3	2

129	EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. <i>Lung Cancer</i> , 2016 , 96, 74-7	5.9	10
128	Recommandations de bonne pratique : surveillance m̃dico-professionnelle des travailleurs expos̃s ou ayant t̃ expos̃s ^ des agents canc̃rog̃nes pulmonaires. <i>Archives Des Maladies Professionnelles Et De L'environnement</i> , 2016 , 77, 579-620	0.1	
127	Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4050-4051	2.2	1
126	BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. <i>European Respiratory Journal</i> , 2015 , 45, 1403-14	13.6	43
125	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology, The</i> , 2015 , 16, 257-65	21.7	1050
124	Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. <i>Clinical Cancer Research</i> , 2015 , 21, 1896-903	12.9	146
123	Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). <i>Lung Cancer</i> , 2015 , 89, 139-45	5.9	8
122	No impact of passive smoke on the somatic profile of lung cancers in never-smokers. <i>European Respiratory Journal</i> , 2015 , 45, 1415-25	13.6	17
121	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 328-37	21.7	102
120	A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. <i>Lung Cancer</i> , 2015 , 90, 397-404	5.9	10
119	Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 121-8	3.5	2
118	Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. <i>Intensive Care Medicine</i> , 2015 , 41, 164-5	14.5	15
117	Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. <i>ClinicoEconomics and Outcomes Research</i> , 2015 , 7, 9-15	1.7	14
116	Current process and future path for health economic assessment of pharmaceuticals in France. <i>Journal of Market Access & Health Policy</i> , 2015 , 3,	3.7	10
115	Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). <i>BMC Cancer</i> , 2015 , 15, 857	4.8	9
114	Aging-related systemic manifestations in COPD patients and cigarette smokers. <i>PLoS ONE</i> , 2015 , 10, e0121539	3.7	26
113	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 763-74	21.7	329
112	A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015 , 20, 783-90	1.8	5

111	Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. <i>Clinical Lung Cancer</i> , 2015 , 16, 100-5	4.9	8
110	Companion Diagnostics-Targeted Therapies Pairings Model-Based Economic Evaluation: Reflection On A General Modeling Framework And Key Methodological Points. <i>Value in Health</i> , 2014 , 17, A565	3.3	
109	Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). <i>Lung Cancer</i> , 2014 , 86, 170-3	5.9	112
108	Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy. <i>European Respiratory Journal</i> , 2014 , 43, 387-96	13.6	62
107	Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. <i>Lung Cancer</i> , 2014 , 85, 415-9	5.9	16
106	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014 , 25, 2147-2155	10.3	19
105	A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2014 , 14, 231	4.8	14
104	Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. <i>Annals of Oncology</i> , 2014 , 25, 1044-52	10.3	117
103	Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. <i>BMC Cancer</i> , 2014 , 14, 953	4.8	6
102	Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3577	2.2	6
101	Continuation of afatinib beyond progression: Results of a randomized, open-label, phase III trial of afatinib plus paclitaxel (P) versus investigator choice chemotherapy (CT) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and afatinib (UX-Lung 5 (LL5)). <i>Journal of Clinical Oncology</i> , 2014 , 32, 8019-8019	2.2	16
100	The association between asthma control, health care costs, and quality of life in France and Spain. <i>BMC Pulmonary Medicine</i> , 2013 , 13, 15	3.5	68
99	Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013 , 145, 1305-11	1.5	18
98	Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study). <i>Lung Cancer</i> , 2013 , 82, 353-7	5.9	11
97	Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). <i>Clinical Lung Cancer</i> , 2013 , 14, 103-7	4.9	10
96	What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients?--Results from the lung cancer economics and outcomes research (LUCEOR) study. <i>Lung Cancer</i> , 2013 , 82, 128-35	5.9	13
95	Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review. <i>Lung Cancer</i> , 2013 , 79, 91-3	5.9	9
94	Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1409-16	8.9	20

93	An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1529-37	8.9	31
92	Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. <i>Annals of Oncology</i> , 2013 , 24, 1548-52	10.3	92
91	Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1997-2003	2.2	453
90	Reply to N. Singh et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1251-2	2.2	
89	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013 , 24, 2875-80	10.3	38
88	Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 906-14	8.9	8
87	Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 997-1003	8.9	71
86	Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents. <i>ClinicoEconomics and Outcomes Research</i> , 2013 , 5, 137-41	1.7	
85	Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1490-502	8.9	65
84	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. <i>European Respiratory Journal</i> , 2012 , 39, 172-9	13.6	31
83	Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions. <i>Respiratory Medicine</i> , 2012 , 106, 467-71	4.6	37
82	Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3516-24	2.2	171
81	Cost effectiveness of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504). <i>BMC Cancer</i> , 2012 , 12, 301	4.8	11
80	A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. <i>Lung Cancer</i> , 2012 , 76, 465-71	5.9	19
79	A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study). <i>Lung Cancer</i> , 2012 , 77, 97-103	5.9	20
78	Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD. <i>BMC Pulmonary Medicine</i> , 2012 , 12, 39	3.5	1
77	Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. <i>ClinicoEconomics and Outcomes Research</i> , 2012 , 4, 269-75	1.7	15
76	Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2012 , 4, 31-7	1.7	19

75	Patient (Pt) and caregiver (Cg) perspectives in non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4-4	2.2	1
74	PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model. <i>Value in Health</i> , 2011 , 14, A454	3.3	2
73	Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: a willingness to pay study. <i>Lung Cancer</i> , 2011 , 72, 114-8	5.9	12
72	Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study. <i>Lung Cancer</i> , 2011 , 74, 264-7	5.9	3
71	Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. <i>Lung Cancer</i> , 2011 , 74, 529-34	5.9	25
70	PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC). <i>Value in Health</i> , 2011 , 14, A440	3.3	2
69	Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007. <i>Respiratory Medicine</i> , 2011 , 105, 595-601	4.6	21
68	Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2011 , 6, e24870	3.7	29
67	Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project-part 1). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1006-15	8.9	43
66	Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). <i>Journal of Thoracic Oncology</i> , 2011 , 6, 576-82	8.9	82
65	« Regards croisés 2009 »: enquête menée auprès de patients atteints de cancer et de professionnels de santé sur la perception de la fatigue et de l'anémie chimio-induite, typologies et enseignements. <i>Oncologie</i> , 2011 , 13, 249-258	1	
64	A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1203-8	3.5	10
63	Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. <i>BMC Medicine</i> , 2011 , 9, 7	11.4	69
62	Interactions between HIV infection and chronic obstructive pulmonary disease: Clinical and epidemiological aspects. <i>Respiratory Research</i> , 2011 , 12, 117	7.3	19
61	Effects of polycythemia on systemic endothelial function in chronic hypoxic lung disease. <i>Journal of Applied Physiology</i> , 2011 , 110, 1196-203	3.7	14
60	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2011 , 27, 2193-201	2.5	3
59	Optimization of small-cell lung cancer chemotherapy with heparin: a comprehensive retrospective study of 239 patients treated in a single specialized center. <i>Chemotherapy</i> , 2011 , 57, 253-8	3.2	8
58	Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 161-8	8.9	29

57	A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). <i>British Journal of Cancer</i> , 2011 , 105, 1123-30	8.7	22
56	Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. <i>Circulation Research</i> , 2011 , 109, 543-53	15.7	100
55	Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a classical strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an optimized strategy allocating the same treatments	2.2	4
54	A randomized study of endobronchial valves for advanced emphysema. <i>New England Journal of Medicine</i> , 2010 , 363, 1233-44 <i>Oncology</i> , 2011 , 29, TPS219-TPS219	59.2	562
53	Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer. <i>Lung Cancer</i> , 2010 , 67, 188-93	5.9	17
52	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010 , 69 Suppl 1, S4-10	5.9	13
51	Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2010 , 69 Suppl 1, S24-30	5.9	11
50	PCN84 COST-EFFECTIVENESS OF ERLOTINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FIT ELDERLY PATIENTS: AN ECONOMICAL ANALYSIS OF A PROSPECTIVE PHASE 2 STUDY (GFPC 0504). <i>Value in Health</i> , 2010 , 13, A267	3.3	2
49	<< Regards croisés 2009 >>: enquête menée auprès de patients atteints de cancer et de professionnels de santé sur la perception de la fatigue et de l'innocuité chimio-induite. <i>Oncologie</i> , 2010 , 12, 239-244	1	5
48	« Regards croisés 2009 » : perceptions croisées des patients atteints de cancer et des professionnels de santé sur les conséquences de la fatigue et de l'innocuité chimio-induite sur la vie quotidienne. <i>Oncologie</i> , 2010 , 12, 375-381	1	4
47	« Regards croisés 2009 » : perceptions croisées des patients atteints de cancer et des professionnels de santé sur leurs relations dans la prise en charge du cancer et de la fatigue. <i>Oncologie</i> , 2010 , 12, 495-501	1	3
46	« Regards croisés 2009 »: perceptions croisées des patients atteints de cancer et des professionnels de santé sur les conséquences de la fatigue et de l'innocuité chimio-induite, analyse des sous-populations. <i>Oncologie</i> , 2010 , 12, 709-717	1	1
45	Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. <i>Clinical Lung Cancer</i> , 2010 , 11, 176-81	4.9	63
44	Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004. <i>BMC Public Health</i> , 2010 , 10, 495	4.1	6
43	Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 7507-7507	2.2	38
42	Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1455-60	2.5	11
41	Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 566-71	10.2	228
40	Role for interleukin-6 in COPD-related pulmonary hypertension. <i>Chest</i> , 2009 , 136, 678-687	5.3	126

39	Management of nosocomial pneumonia on a medical ward: a comparative study of outcomes and costs of invasive procedures. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 165-72	9.5	17
38	Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2009 , 65, 345-50	5.9	46
37	Economics of treatments for non-small cell lung cancer. <i>Pharmacoeconomics</i> , 2009 , 27, 113-25	4.4	31
36	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. <i>Lancet, The</i> , 2009 , 373, 1525-31	4.0	1138
35	A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study). <i>Journal of Thoracic Oncology</i> , 2009 , 4, 364-70	8.9	7
34	Cost-benefit analysis of a simulated institution-based preoperative smoking cessation intervention in patients undergoing total hip and knee arthroplasties in France. <i>Chest</i> , 2009 , 135, 477-483	5.3	19
33	Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2008 , 99, 2006-12	8.7	108
32	A web-based Delphi study on the indications of chest radiographs for patients in ICUs. <i>Chest</i> , 2008 , 133, 1107-12	5.3	41
31	Qualit�de vie et traitement de l'�n�mie chimio-induite dans le cancer bronchopulmonaire : �tude prospective. <i>Revue Des Maladies Respiratoires</i> , 2007 , 24, 41-47	0	1
30	An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. <i>Lung Cancer</i> , 2007 , 57, 72-8	5.9	15
29	PCN3 ECONOMIC IMPACT OF SECOND- AND THIRD-LINE ERLOTINIB TREATMENT OF NON SMALL-CELL LUNG CANCER: A FRENCH OBSERVATIONAL STUDY. <i>Value in Health</i> , 2007 , 10, A322	3.3	2
28	An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 73-81	7	16
27	Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study. <i>Targeted Oncology</i> , 2007 , 2, 63-71	5	1
26	Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis. <i>Current Medical Research and Opinion</i> , 2007 , 23, 1509-15	2.5	27
25	Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 475-476		47
24	The Cost of Lung Cancer Management in France from the Payor's Perspective. <i>Disease Management and Health Outcomes</i> , 2006 , 14, 55-67		3
23	Cost of lung cancer: a methodological review. <i>Pharmacoeconomics</i> , 2006 , 24, 651-9	4.4	24
22	Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: a Markov analysis. <i>Lung Cancer</i> , 2006 , 51, 369-76	5.9	14

21	O-091 A randomized phase II trial of docetaxel alone and in combination with gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2005 , 49, S33	5.9	2
20	Standardized protocol improves asthma management in emergency department. <i>Journal of Asthma</i> , 2004 , 41, 19-25	1.9	10
19	Economics of the clinical management of lung cancer in France: an analysis using a Markov model. <i>British Journal of Cancer</i> , 2004 , 90, 397-402	8.7	41
18	Impact of a multidisciplinary approach to the control of antibiotic prescription in a general hospital. <i>Journal of Hospital Infection</i> , 2003 , 53, 177-82	6.9	49
17	Diagnosis of nosocomial pneumonia in medical ward: repeatability of the protected specimen brush. <i>European Respiratory Journal</i> , 2001 , 18, 157-63	13.6	8
16	Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. <i>European Journal of Clinical Investigation</i> , 2001 , 31, 103-9	4.6	20
15	Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. <i>Clinical Biochemistry</i> , 2000 , 33, 405-10	3.5	26
14	Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 162, 1493-9	10.2	78
13	Empyema of the thorax due to <i>Gemella haemolysans</i> . <i>Journal of Infection</i> , 1999 , 39, 245-6	18.9	11
12	Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 157, 1452-60	10.2	30
11	CPAP titration by an auto-CPAP device based on snoring detection: a clinical trial and economic considerations. <i>European Respiratory Journal</i> , 1998 , 12, 759-63	13.6	34
10	Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. <i>Journal of Clinical Oncology</i> , 1998 , 16, 2700-7	2.2	50
9	Efficacy and toxicity of mitomycin, ifosfamide, and cisplatin (MIP) in patients with inoperable non-small cell lung cancer. <i>Lung Cancer</i> , 1996 , 14, 109-17	5.9	1
8	Pulmonary cryptosporidiosis in the acquired immunodeficiency syndrome. <i>Infection</i> , 1996 , 24, 328-31	5.8	13
7	Risk factors for isolation of <i>Streptococcus pneumoniae</i> with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 1996 , 22, 437-40	11.6	44
6	Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. <i>Clinical Infectious Diseases</i> , 1995 , 21, 628-33	11.6	102
5	Use of the polymerase chain reaction technique on induced-sputum samples for the diagnosis of <i>Pneumocystis carinii</i> pneumonia in HIV-infected patients. A clinical and cost-analysis study. <i>American Journal of Clinical Pathology</i> , 1995 , 104, 72-5	1.9	32
4	Attitudes to prevention among HIV-infected patients: the case of specific prophylaxis for <i>Pneumocystis carinii</i> pneumonia. <i>Health Policy</i> , 1994 , 27, 253-9	3.2	1

- 3 Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. *American Journal of Medicine*, **1993**, 95, 177-87^{2,4} 165
- 2 Cost effectiveness of noninvasive oxygen saturation measurement during exercise for the diagnosis of *Pneumocystis carinii* pneumonia. *The American Review of Respiratory Disease*, **1993**, 147, 1360-3 17
- 1 Causes of pleural effusion in 75 HIV-infected patients. *Chest*, **1993**, 104, 655 5:3 14